SEC Form EFFECT filed by China Pharma Holdings Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | February 14, 2024 4:00 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | February 14, 2024 4:00 P.M. |
Form: | S-3 | ||||||
|
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patentEpidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in ChinaAccording to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.5
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)
Gainers ASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 11.64% to $0.75. The company's market cap stands at $26.9 million. Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 10.99% to $0.19. The market value of their outstanding shares is at $1.2 million. CVRx (NASDAQ:CVRX) stock moved upwards by 9.48% to $12.0. The company's market cap stands at $259.1 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 8.68% to $0.27. Fresh2 Group (NASDAQ:FRES) shares rose 7.56% to $0.34. The market value
Gainers Holdco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. The company's market cap stands at $63.8 million. Entero Therapeutics (NASDAQ:ENTO) shares moved upwards by 8.69% to $2.25. The company's market cap stands at $6.1 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 7.4% to $1.45. The market value of their outstanding shares is at $34.5 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 5.92% to $0.29. Nutex Health (NASDAQ:NUTX) stock increased by 5.53% to $0.57. The market value of their outstanding shares is at $28.3 million. Inspire Veterinary (NASDAQ:IVP) stock increased by 5.05%
Gainers Anitra (AMEX:AZTR) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 12.79% to $3.35. The company's market cap stands at $1.9 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares moved upwards by 9.17% to $0.45. The company's market cap stands at $2.1 million. TRACON Pharma (NASDAQ:TCON) stock rose 8.77% to $1.24. The market value of their outstanding shares is at $3.3 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 6.36% to $1.17. The market value of their outstanding shares is at $7.7 million. China Pharma Holdings, Inc. Common Stock (AM
HAIKOU, China, Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China. It is a medical treatment device for dry eye disease under patent protection;The Company, through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registrat
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-302. The reverse stock split at a ratio of 1-for-5 shares was approved by the Company's Board of Directors through unanimous written consent on October 16, 2023 and adopted by the Company's stockholders
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China. According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic out